Over the past decade, the number of clinical trials using a biosimilar treatment has been on the rise.

GlobalData extracted all biosimilar drug trials from the clinical trial database up to 21 December 2018 and then broke them down by indication.

Biosimilars in clinical trials

The largest indication by biosimilar clinical trial count is rheumatoid arthritis, followed by breast cancer, anaemia, psoriasis and Crohn’s disease.

Industry-sponsored trials were the most common across all the major indications, with the top four indications featuring 89–94.7% industry-sponsored trials. However, in the case of Crohn’s disease, closer to half of the trials had non-industry sponsors (identified in the graph).

This suggests there are more institution and government interest in the development of biosimilars in this indication.

Biosimilar clinical trials for the top 5 indications, by sponsor type

Source: GlobalData

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Reports
Bringing Biosimilars from Bench to Bedside, December 2018, GlobalData, GDHC2195EI